Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A-C Toffart1,2, F Gonzalez3, T Pierret1

  • 1UM Oncologie Thoracique, Service Hospitalo-Universitaire de Pneumologie et Physiologie, Pôle Thorax et Vaisseaux, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.

Revue Des Maladies Respiratoires Actualites
|October 18, 2021
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Four-Year Outcomes of First-Line Nivolumab Plus Ipilimumab for 6 Months Versus Continuation in Patients With Advanced NSCLC: Results of the Randomized IFCT-1701 "DICIPLE" Phase III Trial.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

Innovative therapeutic cancer vaccine PDC<sup>∗</sup>lung01 with or without anti-PD-1: an open-label, dose-escalation phase I/II study in non-small-cell lung cancer.

ESMO open·2025
Same author

Outcomes Analysis of Patients Receiving Local Ablative Therapy for Oligoprogressive Metastatic NSCLC Under First-Line Immunotherapy.

Clinical lung cancer·2024
Same author

[ICU admission for cancer patients with respiratory failure: An ethical dilemma].

Revue des maladies respiratoires·2023
Same author

Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial.

ESMO open·2023
Same author

[Management of immunotherapy in patients with non-small cell lung cancer presenting durable oncological response].

Revue des maladies respiratoires·2022
Same journal

Revue des maladies respiratoires actualites·2022
Same journal

Revue des maladies respiratoires actualites·2022
Same journal

Revue des maladies respiratoires actualites·2022
Same journal

Revue des maladies respiratoires actualites·2022
Same journal

[Highlights in Respiratory Medicine in 2021].

Revue des maladies respiratoires actualites·2022
Same journal

Revue des maladies respiratoires actualites·2022
See all related articles
This summary is machine-generated.

For lung cancer patients experiencing organ failure, intensive care unit (ICU) admission decisions must align with patient wishes and care plans. Early oncologist-patient discussions are crucial for documenting these preferences.

Area of Science:

  • Oncology
  • Intensive Care Medicine
  • Palliative Care

Context:

  • Lung cancer patients admitted to the intensive care unit (ICU) often present with organ failure.
  • Decisions regarding ICU admission intensity require knowledge of the patient's wishes and overall care plan.
  • Physicians managing acute illness may lack information on patient preferences and advance care planning.

Purpose:

  • To emphasize the importance of early discussions between oncologists and lung cancer patients regarding end-of-life care preferences.
  • To highlight the necessity of documenting patient wishes in medical records for ICU admission decisions.
  • To underscore the need for collaboration between oncologists and intensivists to align ICU care with patient goals.

Summary:

  • Lung cancer patients with organ failure require ICU care decisions that respect their wishes and therapeutic project.
Keywords:
Advanced care planningICU trialIntensive care unitOrgan dysfunctionlung neoplasm

Related Experiment Videos

  • Prognostic criteria for ICU admission include patient characteristics, cancer details, and acute disease severity.
  • Effective communication between oncologists and intensivists is vital, particularly during the SARS-CoV-2 pandemic.

    • Impact:

    • Facilitates patient-centered decision-making in critical care for advanced lung cancer.
    • Improves the alignment of intensive care with patients' quality of life goals.
    • Enhances communication and collaboration between oncology and critical care teams.